Latest China Market News

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

International Graphite Limited has reported pilot-scale testwork results exceeding purity targets for expandable graphite, underpinning plans for a European production facility.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

Wide Open Agriculture has made significant strides in expanding its intellectual property and commercial footprint, including a new patent for lupin protein milk and first sales of lupin oil, while progressing plans for a large-scale manufacturing facility in Western Australia.

Merino & Co. reported steady progress in Q2 FY26 with growing demand from China and ongoing investments in brand and manufacturing, despite a tightening cash position.

RooLife Group Ltd has reported a remarkable doubling of its coffee and food sales in China, surpassing A$2.1 million in December 2025 and signaling strong momentum in its data-driven e-commerce strategy.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Osteopore Limited has inked an exclusive collaboration with Majeton to commercialise its cutting-edge 3D-printed bioresorbable implants across China, Hong Kong, and Macau, unlocking significant growth potential in the region.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Treasury Wine Estates moderates its first-half fiscal 2026 outlook due to softer US and China markets, unveiling a major transformation program targeting $100 million in annual cost savings starting next year.

Treasury Wine Estates moderates growth forecasts due to softening demand in key US and China markets, unveiling a major transformation program and cost-saving measures to safeguard brand strength and profitability.